vs
Side-by-side financial comparison of CXApp Inc. (CXAI) and Insight Molecular Diagnostics Inc. (IMDX). Click either name above to swap in a different company.
Insight Molecular Diagnostics Inc. is the larger business by last-quarter revenue ($1.1M vs $1.0M, roughly 1.1× CXApp Inc.). CXApp Inc. runs the higher net margin — -544.1% vs -2015.4%, a 1471.2% gap on every dollar of revenue. On growth, Insight Molecular Diagnostics Inc. posted the faster year-over-year revenue change (-23.4% vs -38.5%). CXApp Inc. produced more free cash flow last quarter ($-3.6M vs $-7.0M). Over the past eight quarters, Insight Molecular Diagnostics Inc.'s revenue compounded faster (154.4% CAGR vs -25.0%).
CXApp Inc. is a technology firm specializing in digital workplace experience solutions. It offers cloud-based software tools for employee engagement, office space optimization, visitor management, and hybrid work coordination, serving mid-to-large enterprises across North America, APAC and Europe.
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
CXAI vs IMDX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0M | $1.1M |
| Net Profit | $-5.6M | $-23.0M |
| Gross Margin | 86.9% | 42.5% |
| Operating Margin | -576.9% | -2057.5% |
| Net Margin | -544.1% | -2015.4% |
| Revenue YoY | -38.5% | -23.4% |
| Net Profit YoY | -56.7% | 31.5% |
| EPS (diluted) | — | $-0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0M | $1.1M | ||
| Q3 25 | $1.1M | $260.0K | ||
| Q2 25 | $1.2M | $518.0K | ||
| Q1 25 | $1.2M | $2.1M | ||
| Q4 24 | $1.7M | $1.5M | ||
| Q3 24 | $1.9M | $115.0K | ||
| Q2 24 | $1.8M | $104.0K | ||
| Q1 24 | $1.8M | $176.0K |
| Q4 25 | $-5.6M | $-23.0M | ||
| Q3 25 | $-3.2M | $-10.9M | ||
| Q2 25 | $-3.1M | $-9.7M | ||
| Q1 25 | $-1.6M | $-6.7M | ||
| Q4 24 | $-3.5M | $-33.5M | ||
| Q3 24 | $-5.4M | $-13.5M | ||
| Q2 24 | $-5.3M | $-4.5M | ||
| Q1 24 | $-5.2M | $-9.1M |
| Q4 25 | 86.9% | 42.5% | ||
| Q3 25 | 89.0% | 53.5% | ||
| Q2 25 | 86.0% | 67.6% | ||
| Q1 25 | 87.7% | 62.0% | ||
| Q4 24 | 86.0% | 40.0% | ||
| Q3 24 | 80.4% | 43.5% | ||
| Q2 24 | 80.0% | 48.1% | ||
| Q1 24 | 82.0% | 25.6% |
| Q4 25 | -576.9% | -2057.5% | ||
| Q3 25 | -343.4% | -4249.2% | ||
| Q2 25 | -336.1% | -1900.0% | ||
| Q1 25 | -306.0% | -318.0% | ||
| Q4 24 | -169.7% | -2262.9% | ||
| Q3 24 | -194.3% | -11752.2% | ||
| Q2 24 | -206.7% | -4453.8% | ||
| Q1 24 | -197.3% | -5265.3% |
| Q4 25 | -544.1% | -2015.4% | ||
| Q3 25 | -283.4% | -4174.6% | ||
| Q2 25 | -256.7% | -1880.7% | ||
| Q1 25 | -132.0% | -312.0% | ||
| Q4 24 | -213.6% | -2255.1% | ||
| Q3 24 | -286.5% | -11733.0% | ||
| Q2 24 | -297.6% | -4355.8% | ||
| Q1 24 | -284.4% | -5186.9% |
| Q4 25 | — | $-0.75 | ||
| Q3 25 | — | $-0.34 | ||
| Q2 25 | — | $-0.30 | ||
| Q1 25 | — | $-0.26 | ||
| Q4 24 | — | $-2.19 | ||
| Q3 24 | — | $-0.98 | ||
| Q2 24 | — | $-0.36 | ||
| Q1 24 | — | $-1.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.1M | $11.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $14.0M | $-31.5M |
| Total Assets | $32.4M | $25.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.1M | $11.6M | ||
| Q3 25 | $5.1M | $18.7M | ||
| Q2 25 | $4.9M | $24.3M | ||
| Q1 25 | $3.9M | $31.0M | ||
| Q4 24 | $4.9M | $8.6M | ||
| Q3 24 | — | $3.4M | ||
| Q2 24 | — | $9.3M | ||
| Q1 24 | — | $5.6M |
| Q4 25 | $14.0M | $-31.5M | ||
| Q3 25 | $15.2M | $-9.2M | ||
| Q2 25 | $14.3M | $1.1M | ||
| Q1 25 | $15.6M | $10.2M | ||
| Q4 24 | $15.6M | $-12.3M | ||
| Q3 24 | $13.6M | $9.7M | ||
| Q2 24 | $16.3M | $22.7M | ||
| Q1 24 | $20.9M | $11.6M |
| Q4 25 | $32.4M | $25.8M | ||
| Q3 25 | $28.5M | $43.9M | ||
| Q2 25 | $29.6M | $50.5M | ||
| Q1 25 | $29.3M | $60.4M | ||
| Q4 24 | $31.8M | $35.1M | ||
| Q3 24 | — | $70.2M | ||
| Q2 24 | — | $74.7M | ||
| Q1 24 | — | $71.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.6M | $-5.5M |
| Free Cash FlowOCF − Capex | $-3.6M | $-7.0M |
| FCF MarginFCF / Revenue | -355.5% | -616.7% |
| Capex IntensityCapex / Revenue | 0.2% | 129.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-10.4M | $-25.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.6M | $-5.5M | ||
| Q3 25 | $-2.8M | $-4.5M | ||
| Q2 25 | $-3.0M | $-6.3M | ||
| Q1 25 | $-979.0K | $-5.9M | ||
| Q4 24 | $-2.7M | $-5.4M | ||
| Q3 24 | $-2.1M | $-5.5M | ||
| Q2 24 | $-1.9M | $-6.0M | ||
| Q1 24 | $-650.0K | $-3.8M |
| Q4 25 | $-3.6M | $-7.0M | ||
| Q3 25 | $-2.8M | $-5.6M | ||
| Q2 25 | $-3.0M | $-6.6M | ||
| Q1 25 | $-984.0K | $-6.2M | ||
| Q4 24 | — | $-5.6M | ||
| Q3 24 | $-2.1M | $-5.6M | ||
| Q2 24 | $-1.9M | $-6.2M | ||
| Q1 24 | $-668.0K | $-3.9M |
| Q4 25 | -355.5% | -616.7% | ||
| Q3 25 | -248.1% | -2135.4% | ||
| Q2 25 | -247.2% | -1279.5% | ||
| Q1 25 | -80.4% | -288.4% | ||
| Q4 24 | — | -374.5% | ||
| Q3 24 | -109.3% | -4884.3% | ||
| Q2 24 | -108.6% | -5931.7% | ||
| Q1 24 | -36.7% | -2189.8% |
| Q4 25 | 0.2% | 129.9% | ||
| Q3 25 | 0.4% | 403.8% | ||
| Q2 25 | 0.9% | 67.4% | ||
| Q1 25 | 0.4% | 14.4% | ||
| Q4 24 | 0.0% | 14.4% | ||
| Q3 24 | 0.2% | 75.7% | ||
| Q2 24 | 0.5% | 183.7% | ||
| Q1 24 | 1.0% | 13.6% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
